| seit 2018 |
Deep learning for prostate cancer MRI diagnosis (Dr. Gabrani, IBM Zürich Research Laboratory, PD Dr. Patak, Klinik Hirslanden Zürich) |
| seit 2016 |
Co-Coordinator, Phase IIIb randomized trial comparing irradiation plus long-term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer. A joint study of the EORTC ROG and GUCG (Pegasus), EORTC protocol 1414 ROG-GUCG |
| seit 2014 |
MRI-characteristics of locally advanced Prostate Cancer (Prof. Hadaschik, PD Dr. Wetter, Universität Essen) |
| seit 2013 |
Co-PI, Perioperative anti-PD-L1 antibody durvalumab (MEDI4736) in combination with neoadjuvant chemotherapy in patients with operable urothelial cancer, SAKK 06/17 |
| seit 2011 |
Movember Global Action Plan 6 (GAP6) Oligometastatic Prostate cancer, Steering committee member (Movember foundation, Australia, USA) |
| seit 2007 |
Identification of genomic determinants of tumor and metastasis heterogeneity of high risk prostate cancer and development of a lethal prostate cancer panel. (Prof. Rubin, PD Dr. Kruithof de Julio, Bern) |
